Cellectis plans Phase 1 trial of .HEAL-101 in China, expects initial data in second half of 2027
CLLS•Cellectis reported preclinical results for its gene-editing candidate .HEAL-101 and plans a Phase 1 investigator-initiated trial in China, with preliminary clinical data expected in the second half of 2027.
1. Preclinical findings
A single dose of .HEAL-101 substantially reduced triglycerides in a mouse disease model, with editing activity restricted to the liver. Cellectis said it will present the findings on October 29 at the European Society of Gene and Cell Therapy congress in Hamburg.
2. Trial plans
A Phase 1 investigator-initiated trial is planned in China, and preliminary clinical data are expected in the second half of 2027.
